JORDAN SHERFEY: Open Payments
NPI 1346971413 · LONGVIEW, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,762 in 72 payments from 9 companies in 2025. Trend: 2023 $1,147 · 2024 $3,561 · 2025 $1,762
Food & beverage: $1,762
| Company | Payments | Amount |
|---|---|---|
| CSL Behring | 23 | $640 |
| AstraZeneca Pharmaceuticals LP | 15 | $313 |
| GENZYME CORPORATION | 9 | $217 |
| Regeneron Healthcare Solutions, Inc. | 6 | $150 |
| GlaxoSmithKline, LLC. | 8 | $145 |
| Amgen Inc. | 5 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $47 |
| BioCryst US Sales Co., LLC | 1 | $41 |
Products named: Haegarda, DUPIXENT, TEZSPIRE, Hizentra, AIRSUPRA, NUCALA, Andembry, CUVITRU.
Industry payments across WA — which companies pay providers there.
